In a landmark development for pediatric medicine, the U.S. Food and Drug Administration (FDA) has officially approved the expansion of ViiV Healthcare’s Tivicay PD (dolutegravir) to treat HIV-1 in the youngest of patients. The approval marks a significant shift in the treatment landscape, allowing the drug to be administered to newborns weighing as little as 2 kilograms (approximately 4.4 pounds) from their first day of life. This decision effectively eliminates the previous minimum-age requirement, providing a vital tool for clinicians tasked with managing perinatally acquired HIV.
The Critical Need for Pediatric HIV Therapeutics
For years, the medical community has grappled with a "treatment gap" regarding HIV-positive infants. While antiretroviral therapy (ART) has revolutionized HIV management for adults and older children, neonatal options have remained historically limited. According to data from UNICEF, the stakes for these patients are staggeringly high: approximately 50% of infants living with HIV do not survive beyond their second birthday if they do not receive timely and appropriate medical intervention.
By lowering the weight threshold to 2 kg and removing the age floor, the FDA is addressing an urgent unmet need. The ability to initiate treatment immediately—often within the first few hours or days of life—is paramount to suppressing viral replication and preventing the rapid progression of the disease in the developing immune systems of newborns.
A Chronology of Progress: From Adults to Neonates
The journey of Tivicay (dolutegravir) from an adult therapeutic to a neonatal life-saver has been a deliberate, data-driven progression.
- August 2013: The FDA granted the first approval for Tivicay, specifically targeting adults and adolescents aged 12 or older who weighed at least 40 kg (88.2 lbs). This set the foundation for the drug’s use as a potent integrase strand transfer inhibitor (INSTI).
- 2020: The FDA expanded the indication to include the dispersible tablet formulation, Tivicay PD. At this stage, the drug was cleared for use in pediatric patients at least four weeks old who weighed at least 3 kg (6.6 lbs).
- 2025 (CROI Presentation): Preliminary results from the IMPAACT 2023 study were presented at the Conference on Retroviruses and Opportunistic Infections (CROI), offering early evidence that the drug was both safe and pharmacokinetically stable in a cohort of infants starting treatment within the first five days of life.
- August 2026: The FDA officially granted the expanded label, allowing for the treatment of newborns weighing at least 2 kg, marking the first time a second-generation INSTI has been approved for this specific age and weight demographic.
Supporting Clinical Data: The IMPAACT 2023 Study
The regulatory submission for this expansion was anchored by the NIH-funded IMPAACT 2023 study, a multicenter, phase 1 clinical trial. The study was meticulously designed to establish the safety, tolerability, and pharmacokinetic (PK) profile of dolutegravir in the most vulnerable population: neonates during their first four to six weeks of life.
Researchers enrolled 48 mother-infant pairs across clinical sites in the United States, South Africa, and Thailand. The study participants, all newborns exposed to HIV-1 and meeting the 2 kg weight requirement, were administered Tivicay PD from birth for a duration of up to six weeks. These infants were concurrently treated with standard-of-care antiretroviral medications used to mitigate mother-to-child transmission.
The findings were highly encouraging. Following a 16-week monitoring period, the data showed that drug exposure levels in the newborns were comparable to those observed in adults, where the efficacy of dolutegravir is well-established. Furthermore, the safety profile was consistent with observations in older pediatric populations, with no significant unexpected adverse events reported. A specialized cohort of 15 infants, who began a regimen of 5 mg of Tivicay PD every other day followed by daily dosing, confirmed that this tailored approach could successfully manage viral load during the critical early neonatal period.
Expert Perspectives and Official Responses
The medical community has lauded the approval as a long-overdue advancement. Dr. Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and the lead investigator of the IMPAACT 2023 study, emphasized the transformative nature of the FDA’s decision.
"For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Dr. Clarke stated. She highlighted that this approval is not merely a label change but a fundamental shift in the standard of care for neonatal HIV.
From a regulatory standpoint, the FDA’s decision to grant the application Priority Review status underscores the agency’s commitment to expediting treatments for pediatric infectious diseases. By facilitating the development of a dispersible tablet, the FDA and ViiV Healthcare have ensured that the medication is not only effective but also practical for administration to infants who cannot swallow standard pills.
Implications for Global Health and Market Dynamics
While perinatally acquired HIV is relatively rare in the United States—with fewer than 50 cases reported annually since 2018 and a vertical transmission rate of 1% or less—the global implications of this approval are profound. In many low- and middle-income countries, the burden of pediatric HIV remains high, and the availability of a robust, pediatric-friendly formulation like Tivicay PD is essential to global efforts to eliminate mother-to-child transmission.
Commercial Performance and Portfolio Growth
From a business perspective, the approval comes at a time when ViiV Healthcare’s parent company, GSK, is navigating a shifting HIV market. While the standalone Tivicay brand has seen sales plateau—with GSK reporting £1.323 billion in 2025 sales, a slight 2% decline—the company’s broader HIV portfolio continues to demonstrate significant resilience.
The growth engine for the firm has shifted toward newer, long-acting formulations and combination therapies. In 2025, GSK’s wider HIV portfolio generated £7.687 billion, an 11% increase at constant exchange rates. The success of drugs such as Dovato, Cabenuva, and Apretude has effectively offset the market saturation of older products. The approval of Tivicay PD for newborns serves as a strategic reinforcement of the company’s commitment to the HIV lifecycle, ensuring that their therapeutic solutions span from birth through adulthood.
Conclusion: A Future-Proofing Strategy
The approval of Tivicay PD for newborns weighing at least 2 kg is a milestone that transcends simple pharmaceutical labeling. It represents a victory for neonatal care, providing clinicians with a proven, second-generation integrase inhibitor that can be safely administered at the most critical juncture of an infant’s life.
As pediatric HIV management continues to evolve, the integration of such therapies into clinical practice will be vital. By prioritizing the unique physiological needs of the smallest patients, the healthcare industry is moving closer to a future where, despite the challenges of HIV, newborns can start their lives with the best possible protection and the greatest potential for long-term health. The success of the IMPAACT 2023 study serves as a blueprint for future pediatric drug development, proving that with rigorous clinical research and targeted regulatory support, even the most complex treatment gaps can be successfully closed.
About the Author
